BACKGROUND: Treatment with chimeric antigen receptor-T (CAR-T) cells has shown promising effectiveness in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), although the process of preparing for this therapy usually takes a long time. We have recently created CD19 Fast-CAR-T (F-CAR-T) cells, which can be produced within a single day. The objective of this study was to evaluate and contrast the effectiveness and safety of CD19 F-CAR-T cells with those of CD19 conventional CAR-T cells in the management of R/R B-ALL. METHODS: A multicenter, retrospective analysis of the clinical data of 44 patients with R/R B-ALL was conducted. Overall, 23 patients were administered with innovative CD19 F-CAR-T cells (F-CAR-T group), whereas 21 patients were given CD19 conventional CAR-T cells (C-CAR-T group). We compared the rates of complete remission (CR), minimal residual disease (MRD)-negative CR, leukemia-free survival (LFS), overall survival (OS), and the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between the two groups. RESULTS: Compared with the C-CAR-T group, the F-CAR-T group had significantly higher CR and MRD-negative rates (95.7% and 91.3%, respectively; 71.4% and 66.7%, respectively; P = 0.036 and P = 0.044). No significant differences were observed in the 1-year or 2-year LFS or OS rates between the two groups: the 1-year and 2-year LFS for the F-CAR-T group vs.C-CAR-T group were 47.8% and 43.5% vs. 38.1% and 23.8% (P = 0.384 and P = 0.216), while the 1-year and 2-year OS rates were 65.2% and 56.5% vs. 52.4% and 47.6% (P = 0.395 and P = 0.540). Additionally, among CR patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T-cell therapy, there were no significant differences in the 1-year or 2-year LFS or OS rates: 57.1% and 50.0% vs. 47.8% and 34.8% (P = 0.506 and P = 0.356), 64.3% and 57.1% vs. 65.2% and 56.5% (P = 0.985 and P = 0.883), respectively. The incidence of CRS was greater in the F-CAR-T group (91.3%) than in the C-CAR-T group (66.7%) (P = 0.044). The incidence of ICANS was also greater in the F-CAR-T group (30.4%) than in the C-CAR-T group (9.5%) (P = 0.085), but no treatment-related deaths occurred in the two groups. CONCLUSION Compared with C-CAR-T-cell therapy, F-CAR-T-cell therapy has a superior remission rate but also leads to a tolerably increased incidence of CRS/ICANS. Further research is needed to explore the function of allo-HSCT as an intermediary therapy after CAR-T-cell therapy.

Objective To investigate the therapeutical effect of triptolide (TP) on subarachnoid hemorrhage (SAH) in rats and its underlying mechanisms.Methods Endovascular perforation technique was used to establish SAH models.TP was used to treat SAH rats by intraperitoneal injection.Rats were randomly divided into control group,SAH 3 d group,SAH 3 d + DMSO group and SAH 3 d + TP group.Pathologic change was observed in rat cortex by HE staining.Cell apoptosis was evaluated by TUNEL assay.Iba-1 considered as microglia marker was assessed by immunohistochemistry.The levels of inflammatory factors including IL-6,IL-1 β and TNF-o were detected by ELISA.Results Compared with control group,pathologic changes,such as cell edema,nuclear pyknosis were more obviously;the number of apoptosis cell,the expression of Iba-1 and the level of inflammatory factors including IL-6,IL-1β and TNF-α were all increased in the cortex of SAH 3 d group,SAH 3 d + DMSO group and SAH 3 d + TP group (P ＜ 0.05).There were no significant differences in pathologic changes,the number of apoptosis cells,the expression of Iba-1 and the levels of inflammatory cytokines in the brain cortex between SAH 3 d group and SAH 3 d + DMSO group (P ＞ 0.05).Compared with SAH 3 d group and SAH 3 d + DMSO group,pathologic changes were alleviated,and the number of apoptosis cells,the expression of Iba-1 and the levels of inflammatory cytokines including IL-6,IL-1β and TNF-α were all decreased in the brain cortex in SAH 3 d + TP group.Conclusion TP could alleviate the pathologic changes,reduce the cell apoptosis and inhibit the microglia activation in rat brain cortex after SAH,and the neuroprotective effect of TP might be associated with the decreased levels of inflammatory cytokines.

Objective To study the preventive effects of rh ub arb and dexamethasone(DXM) on stress ulcer. Methods A total of 80 healthy SD rats were made into stress ulcer animal model with tend cold. They were randomly assigned into four groups, including normal control group(20) , DXM intervention group(20), rhubarb intervention group(20) and rhubarb & DXM i ntervention group(20).All of them were observed for the incidence of stress ulce r. Results The stress ulcer incidence were the same in DXM stress ulcer group and normal control group. The stress ulcer incidence in rhuba rb and DXM group was the lowest. Conclusion The DXM doesn't increase the incidence of stress ulcer, while the rhubarb with DXM does decreas e the incidence of stress ulcer.